Efficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis

Simple item page
dc.contributor.authorVan Rensburg C.J.
dc.contributor.authorHoniball P.J.
dc.contributor.authorGrundling H.D.K.
dc.contributor.authorVan Zyl J.H.
dc.contributor.authorSpies S.K.
dc.contributor.authorEloff F.P.
dc.contributor.authorSimjee A.E.
dc.contributor.authorSegal I.
dc.contributor.authorBotha J.F.
dc.contributor.authorCariem A.K.
dc.contributor.authorMarks I.N.
dc.contributor.authorTheron I.
dc.contributor.authorBethke T.D.
dc.date.accessioned2011-05-15T16:15:18Z
dc.date.available2011-05-15T16:15:18Z
dc.date.issued1996
dc.description.abstractBackground: Pantoprazole is a substituted benzimidazole which is a potent inhibitor of gastric acid secretion by its action upon H+,K+-ATPase. Methods: Pantoprazole 40 mg and 80 mg were compared in a randomized double-blind study in 192 out-patients with stage II or III (Savary-Miller classification) reflux oesophagitis. Patients received either pantoprazole 40 mg (n = 97) or pantoprazole 80 mg (n = 95), once daily before breakfast for 4 weeks. Treatment was extended for a further 4 weeks if the oesophagitis had not healed. Results: After 4 weeks complete healing of the reflux oesophagitis was seen in 78% of protocol-correct patients given pantoprazole 40 mg daily (n = 86), and in 72% in the 80 mg (n = 87) group. The cumulative healing rates after 8 weeks were 95 and 94%, respectively (P > 0.05, Cochran-Mantel-Haenszel), and time until healing of oesophagitis comparable in both groups. Differences between doses were also not significant in an intention-to-treat analysis. Both dosing schedules were well tolerated and the patients experienced remarkable symptom relief. No adverse event or changes in laboratory values of clinical significance could definitely be ascribed to the trial medication. Conclusion: The 40 mg pantoprazole dosage is comparable to 80 mg in reflux oesophagitis, both in efficacy and tolerability.
dc.description.versionArticle
dc.identifier.citationAlimentary Pharmacology and Therapeutics
dc.identifier.citation10
dc.identifier.citation3
dc.identifier.issn02692813
dc.identifier.other10.1111/j.0953-0673.1996.00397.x
dc.identifier.urihttp://hdl.handle.net/10019.1/13276
dc.subjectpantoprazole
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectcontrolled study
dc.subjectdiarrhea
dc.subjectdouble blind procedure
dc.subjectdrug efficacy
dc.subjectdrug tolerability
dc.subjectfemale
dc.subjectheadache
dc.subjecthuman
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmulticenter study
dc.subjectoral drug administration
dc.subjectpriority journal
dc.subjectrandomized controlled trial
dc.subjectreflux esophagitis
dc.subject2-Pyridinylmethylsulfinylbenzimidazoles
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectAged, 80 and over
dc.subjectBenzimidazoles
dc.subjectDouble-Blind Method
dc.subjectEnzyme Inhibitors
dc.subjectEsophagitis, Peptic
dc.subjectFemale
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectOmeprazole
dc.subjectProton Pumps
dc.subjectSulfoxides
dc.titleEfficacy and tolerability of pantoprazole 40 mg versus 80 mg in patients with reflux oesophagitis
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications